{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:54:16Z","timestamp":1759366456191,"version":"build-2065373602"},"reference-count":109,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.revmed.2014.10.364","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T16:23:50Z","timestamp":1414772630000},"page":"328-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["La r\u00e9volution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques"],"prefix":"10.1016","volume":"36","author":[{"given":"G.","family":"Sauv\u00e8tre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2014.10.364_bib0005","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"4","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"key":"10.1016\/j.revmed.2014.10.364_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/asheducation-2004.1.407","article-title":"Recent advances in thrombotic thrombocytopenic purpura","author":"Sadler","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.revmed.2014.10.364_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00467-008-0863-5","article-title":"Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children","volume":"24","author":"Loirat","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0025","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0030","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood-2010-04-280479","article-title":"Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)","volume":"116","author":"Feys","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0035","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2003-11-3888","article-title":"Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins","volume":"103","author":"Studt","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0040","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2010.03772.x","article-title":"HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 defi ciency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians","volume":"8","author":"Coppo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1538-7836.2009.03692.x","article-title":"Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link","volume":"8","author":"Scully","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00277-011-1384-z","article-title":"The role of human leukocyte antigens as predisposing and\/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura","volume":"91","author":"John","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/trf.12263","volume":"54","author":"Morgand","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2014.10.364_bib0060","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2014.10.364_bib0065","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0070","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2014.10.364_bib0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1537-2995.2004.00626.x","article-title":"Severe deficiency of VWFcleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients","volume":"44","author":"Raife","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2014.10.364_bib0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.revmed.2013.02.028","article-title":"Thrombotic thrombocytopenic purpura do not ignore cardiac involvement","volume":"35","author":"Puyade","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.10.364_bib0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2008.01112.x","article-title":"Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review","volume":"81","author":"Wahla","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/clc.20731","article-title":"Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience","volume":"33","author":"Gandhi","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thromb Heamost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0100","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1537-2995.2007.01534.x","article-title":"Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review","volume":"48","author":"Hawkins","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2014.10.364_bib0105","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/ndt\/gfl127","article-title":"Acute myocardial infarction in thrombotic microangiopathies-clinical characteristics, risk factors, and outcome","volume":"21","author":"Patschan","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2014.10.364_bib0110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410230411","article-title":"Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura","volume":"23","author":"Devinsky","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0049-0172(94)90073-6","article-title":"Systemic lupus erythematosus complicated by thrombotic microangiopathy","volume":"24","author":"Jain","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.10.364_bib0120","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Thrombotic microangiopathies reference center. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA reference center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2014.10.364_bib0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0130","first-page":"A755","article-title":"A prospective open label trial of B-cell depletion with Rituximab in refractory systemic vasculitis","volume":"14","author":"Smith","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2014.10.364_bib0140","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of Fc gamma RIIIa genotype to degree of B-cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.10.364_bib0150","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0155","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"Van der Kolk","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0160","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0165","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0170","first-page":"918","article-title":"Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms","volume":"87","author":"Voso","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2014.10.364_bib0175","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0180","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.10.364_bib0185","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0190","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B-cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0195","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0200","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.1982.03320350037025","article-title":"Treatment of thrombotic thrombocytopenic purpura with vincristine","volume":"247","author":"Gutterman","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2014.10.364_bib0205","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0609.1994.tb00649.x","article-title":"Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma exchange","volume":"52","author":"Bobbio-Pallavicini","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.2830350105","article-title":"Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis","volume":"35","author":"Welborn","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00277-001-0395-6","article-title":"Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura","volume":"81","author":"Ferrara","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0220","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Thrombotic microangiopathies reference center. Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2014.10.364_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-1005062","article-title":"Therapy of thrombotic thrombocytopenic purpura: an overview","volume":"7","author":"Bukowski","year":"1981","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0230","first-page":"349","article-title":"Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?","volume":"53","author":"Dubois","year":"2010","journal-title":"Can J Surg"},{"key":"10.1016\/j.revmed.2014.10.364_bib0235","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","article-title":"An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"136","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0245","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0250","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1538-7836.2006.01909.x","article-title":"An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura","volume":"4","author":"Cataland","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0255","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ajh.21281","article-title":"Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura","volume":"83","author":"Cataland","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0260","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1537-2995.2012.03944.x","article-title":"Cyclosporin a therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature","volume":"53","author":"Yilmaz","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2014.10.364_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0270","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2014.10.364_bib0275","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0609.2009.01292.x","article-title":"Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13 deficiency: a report of four cases and a systematic review of the literature","volume":"83","author":"Elliott","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0280","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","article-title":"Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and auto-immune haemolytic anaemia","volume":"97","author":"Heidel","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0290","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0295","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0300","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0305","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0310","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.lpm.2011.10.024","article-title":"Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura","volume":"41","author":"Coppo","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0315","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2014.10.364_bib0320","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jca.20172","article-title":"Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature","volume":"23","author":"Jasti","year":"2008","journal-title":"J Clin Apher"},{"key":"10.1016\/j.revmed.2014.10.364_bib0325","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1160\/TH07-12-0753","article-title":"Rituximab as preemptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies","volume":"101","author":"Bresin","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0330","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.21439","article-title":"Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature","volume":"84","author":"Ling","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0335","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00277-010-0968-3","article-title":"Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab","volume":"89","author":"Chemnitz","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study","volume":"43","author":"de la Rubia","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.revmed.2014.10.364_bib0345","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MBC.0b013e3283529184","article-title":"Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature","volume":"23","author":"Montoya","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.revmed.2014.10.364_bib0350","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1179\/1607845412Y.0000000073","article-title":"Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases","volume":"18","author":"Peque\u00f1o-Lu\u00e9vano","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.revmed.2014.10.364_bib0355","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.10213","article-title":"Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis","volume":"71","author":"Jillella","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0365","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2014.10.364_bib0370","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2010-06-291831","article-title":"Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory auto-immune cytopenias","volume":"116","author":"G\u00f3mez-Almaguer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0375","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic auto-immune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0380","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Experience of the French thrombotic microangiopathies reference center","volume":"124","author":"Miguel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0385","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0390","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0400","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2014.10.364_bib0405","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1182\/blood-2008-03-140905","article-title":"Unleashed platelets in aHUS","volume":"111","author":"St\u00e5hl","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0410","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(02)08560-4","article-title":"Combined kidney and liver transplantation for familial haemolytic uraemic syndrome","volume":"359","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2014.10.364_bib0415","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00467-013-2722-2","article-title":"Liver\u2013kidney transplantation to cure atypical HUS: still an option post-eculizumab?","volume":"29","author":"Saland","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0420","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.4049\/jimmunol.180.9.6385","article-title":"A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic sydrome and leads to impaired alternative pathway cofactor activity","volume":"180","author":"Blom","year":"2008","journal-title":"J Immunol"},{"issue":"361","key":"10.1016\/j.revmed.2014.10.364_bib0425","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic uremic syndrome","volume":"23","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0430","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0435","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.revmed.2014.10.364_bib0440","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"8","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2014.10.364_bib0445","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5","volume":"22","author":"de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0450","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.2006091069","article-title":"Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells","volume":"18","author":"Heinen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0455","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2014.10.364_bib0460","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.10.364_bib0465","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2012.07.028","article-title":"Focus on eculizumab","volume":"61","author":"Schmidtko","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2014.10.364_bib0470","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.revmed.2014.10.364_bib0475","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00467-013-2423-x","article-title":"Atypical HUS: time to take stock of current guidelines and outcome measures?","volume":"28","author":"Rees","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0480","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.12718","article-title":"How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome","volume":"164","author":"Scully","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0485","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0490","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","article-title":"Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab","volume":"28","author":"Gulleroglu","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0495","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00467-013-2709-z","article-title":"Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement","volume":"29","author":"Hu","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0500","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0505","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","article-title":"Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome","volume":"27","author":"Vilalta","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0510","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00467-012-2130-z","article-title":"Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count","volume":"27","author":"Dorresteijn","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0515","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-011-1989-4","article-title":"Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings","volume":"26","author":"Tschumi","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0520","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.10.364_bib0525","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.revmed.2014.10.364_bib0530","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2014.10.364_bib0535","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","article-title":"Successful treatment of DEAP-HUS with eculizumab","volume":"29","author":"Noone","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0540","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0090-1229(90)90067-Z","article-title":"Combined complete C5 and partial C4 deficiency in humans: clinical consequences and complement-mediated functions in vitro","volume":"55","author":"Gianella-Borradori","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.revmed.2014.10.364_bib0545","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr Nephrol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866314010479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866314010479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:34:51Z","timestamp":1759336491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866314010479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":109,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0248866314010479"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2014.10.364","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La r\u00e9volution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2014.10.364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}